CML Publications of the Month
As part of our monthly news service we would like to make you aware of important CML publications. From the many papers published in September, Professor Timothy Hughes has selected topical, interesting papers for your perusal. Papers with a clinical, scientific and low and middle income country focus are shared.
September 2026
Clinical CML papers
First line asciminib in chronic myeloid leukemia:
a quest for the “Holy Grail” of tolerability
Rea D. Haematologica, September 2026
(epub ahead of print) – open access publication
Chronic myeloid leukemia is not a familial disease…
or maybe it is?
Lipton JH. Leuk Res, September 2026
(epub ahead of print)
Characterizing bleeding adverse events associated with BCR-ABL tyrosine kinase inhibitors: insights from FAERS reports
Liang R et al. Front Oncol, September 2026
– open access publication
Treatment-free remission and immune profiling after frontline second-generation tyrosine kinase inhibitor therapy in chronic myeloid leukemia
Takahashi N et al. Blood Adv, September 2026 – open access publication
Dose optimization of dasatinib in chronic-phase chronic myeloid leukemia:
A systematic review and meta-analysis of 50 mg versus 100 mg once daily
Abdulgayoom M et al. Clin Lymphoma Myelom Leuk, September 2026
– open access publication
The prevalence and clinical impact of bone marrow fibrosis in chronic myeloid leukemia
Yousefi A et al. Acta Hematol, September 2026 (epub ahead of print)
Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study
Mulas O et al. Leuk Res, September 2026
Evaluation of BCR::ABL1 positivity in peripheral blood neutrophils enables the diagnosis of de novo blast phase chronic myeloid leukemia with additional structural abnormalities of the Philadelphia chromosome
Sakai H et al. Intern Med, September 2026 (epub ahead of print) – open access publication
Adverse events, quality of life, and work impairment in patients with chronic myeloid leukemia (CML) – a survey of first- and second-line tyrosine kinase inhibitor (TKI) intolerance in the US
Schoenbek K et al. Leuk Lymphoma, September 2026 (epub ahead of print)
– open access publication
Arterial occlusive events in chronic myeloid leukemia patients on TKIs: A real-world study including a large proportion of older patients
Yanai Y et al. Int J Hematol, September 2026 (epub ahead of print) – open access publication
Treatment-free remission in patients with prior tyrosine kinase inhibitor failure is not influenced by previous BCR::ABL1 kinase domain mutations
Claudiani S et al. Br J Haematol, September 2026 (epub ahead of print) – open access publication
Treatment-Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure
Ureshino H, Kimura S., Cancer Sci, September
- open access publication
Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data
Lipton J.H., et al. Blood Reviews, September 2026 – open access publication
Scientific CML papers
Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia
Pagani IS et al. Hemasphere, September 2026 – open access publication
Myeloid blast phase of chronic myeloid leukemia with co-occurring t(11;12) (p15;q13)/NUP98: HOXC12: a novel NUP98 fusion partner
Khan A et al. Haematologica, September 2026 – open access publication
Post-hoc long-read sequencing links leukemic mutation status to single-cell transcriptomes
Papavasileiou S et al. Eur J Hemaol, September 2026 (epub ahead of print)
– open access publication
Do FLT3 and KIR3BL1 converge on a common immune surveillance axis in treatment-free remission in chronic myeloid leukemia
Fujita M and Ureshino H. Leukemia, September 2026
Pediatric CML papers
Population pharmacokinetics of bosutinib in children with Philadelphia chromosome-positive chronic myelogenous leukemia based on a phase I dose-finding trial (ITCC-054/COG AAML 1921) and pediatric recommended phase II dosage evaluation
Wu JH et al. Clin Pharmacokinet, September 2026 – open access publication
Efficacy and safety of tyrosine kinase inhibitor combined with venetoclax based regimen in pediatric patients with chronic myeloid leukemia in the blast phase:
A single-centre retrospective study
Zheng F et al. Pediatr Blood Cancer, September 2026
Neutrophilic panniculitis in a pediatric patient receiving ponatinib
Hathaway JS et al. Pediatr Dermatol, Sept – Oct 2026
Imatinib treatment and vaccination in an infant with chronic myeloid leukemia diagnosed when 40 days old
Dogru O., et al., Blood Global Hematology, September 2026 – open access publication
LMIC CML papers
Cost effectiveness analysis of asciminib in patients with chronic phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors in Colombia
Ceballos M et al. Value Health Reg Issues, September 2026
(epub ahead of print) – open access publication
Flow cytometry assessment of CD26(+) leukemic stem cells in chronic myeloid leukemia
Sarjana et al. Indian J Hematol Blood Transfus, September 2026
Validation of EUTOS long-term survival score in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitor experience from a low-middle income country
Zafar S et al. Indian J Hematol Blood Transfus, September 2026
Revisiting asciminib resistance: from binding affinity to allosteric disruption in BCR::ABL1 leukemias
Sayitoğlu M et al. Turk J Hematol, September 2026 (epub ahead of print) – open access publication
Ponatinib in chronic myeloid leukemia refractory to multiple tyrosine kinase inhibitors: Data from a tertiary care centre in India
Baalamurugan KT et al. Indian J Hematol Blood Transfus, September 2026